Overview

Tafluprost Preservative Free Switch Study

Status:
Completed

Trial end date:
2020-02-01

Target enrollment:

Participant gender:

Summary

This study is conducted to document the effect of switching from preserved prostaglandin analogues monotherapy to preservative free tafluprost 0.0015%. The endpoints analyzed are side effect improvement in these patients.

Phase:

Phase 4

Details

Lead Sponsor:

Tun Hussein Onn National Eye Hospital